Keensight Capital to acquire a majority stake in Axxam, a leading European partner research organization in life sciences

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Axxam, a profitable and leading innovative Partner Research Organization (“iPRO”) in the life sciences industry. According to the terms of the agreement, Keensight Capital will acquire a majority stake in Axxam from the current shareholders, including Bayer SpA and Zambon Company SpA.

Scroll to Top